Genflow Biosciences has advanced patent protection for a SIRT6 variant derived from centenarian genetics, designed to address non-alcoholic fatty liver disease and steatohepatitis. The company's lead candidate, GF-1002, entered proof-of-concept testing in aged dogs in March 2025, representing a translational step toward clinical validation in metabolic dysfunction.
Key Points
- Centenarian-derived SIRT6 variant targets fatty liver disease prevention and treatment
- US patent application published; European application nearing grant stage
- Proof-of-concept trial in aged dogs began March 2025
Longevity Analysis
SIRT6 activation represents a direct intervention on metabolic and regenerative capacity, two functions that decline predictably with age and correlate strongly with late-life disease burden. Fatty liver disease—now prevalent across all ages—reflects a fundamental breakdown in how the body processes lipids and maintains hepatic function. A therapy sourced from centenarian genetics carries the implicit advantage of having operated successfully across a human lifespan; whether the variant translates that advantage into pharmacologic benefit requires clinical evidence. The shift from patent procedurals to animal testing marks a critical transition from intellectual property strategy to biological validation.
Original published by LT Wire.